Jazz Pharmaceuticals plc Announces Full Year And Fourth Quarter 2013 Financial Results

DUBLIN, Feb. 25, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter ended December 31, 2013 and provided financial guidance for 2014.

"2013 was an outstanding year as we delivered strong top-line growth, generated significant cash flow and executed on our corporate development strategy," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals plc. "Our existing products delivered strong growth and, with our recently announced acquisitions, we look forward to launching Defitelio® (defibrotide) in Europe during 2014 and to advancing the development of new treatments for patients with unmet medical needs through our expanded pipeline."

Help employers find you! Check out all the jobs and post your resume.